Christopher Brightling on tezepelumab in patients with moderate-to-severe uncontrolled asthma

The Lancet Respiratory Medicine in conversation with - A podcast by The Lancet Group

Categories:

Education

Christopher Brightling discusses the effect of blocking thymic stromal lymphopoietin (TSLP) with tezepelumab in patients with moderate-to-severe uncontrolled asthma. Read the full article: https://www.thelancet.com/journals/lanres/article/PIIS2213-2600(21)00226-5/fulltext Continue this conversation on social! Follow us today at... https://thelancet.bsky.social/ https://instagram.com/thelancetgroup https://facebook.com/thelancetmedicaljournal https://linkedIn.com/company/the-lancet https://yo...